Fig. 5: Safety of MCLA-145 in a repeat dose non-human primate study.

a Schematic showing the design for the repeat dose safety study; b mean serum concentrations of MCLA-145 measured over one cycle (n = 10 animals for vehicle and 100 mg/kg, n = 6 animals for other treatment groups); c mean maximum serum concentration (C_max) and area under the curve (AUC) at 10 mg/kg (blue), 30 mg/kg (green) and 100 mg/kg (orange) of MCLA-145 measured 24 h after the first dose and 24 h after the fifth dose combined for males and females; n = 10 animals for vehicle and 100 mg/kg, n = 6 animals for other treatment groups, error bars are mean ± SD); d Mean serum concentrations of AST and ALT and e mean number of circulating neutrophils and platelets measured over the study period at the indicated doses (n = 10 animals for vehicle and 100 mg/kg, n = 6 animals for other treatment groups, error bars are SD). Reference mean (male and female bold blue and pink lines respectively) and mean +1 or −1 SD (male and female bold blue and pink lines respectively) as previously reported;⁶⁹ f Number of circulating B (CD20⁺), NK (CD16⁺) and T cells (CD3⁺) with CD4⁺ and CD8⁺ T cell numbers and proportion of different subpopulations shown for the 100 mg/kg/week dose group or vehicle, mean ± SD of male and female groups combined (n = 10 animals).